Cascador Health

What Cascador Health does

Cascador Health is a Belgian health-data platform company founded in 2021 that unlocks real-world healthcare data (RWD) from European hospitals and transforms it into real-world evidence (RWE) for pharmaceutical, medtech, and academic customers. Its core technology is the Cascador Digital Suite, including the Cascador Edge/Merge federated platform, which keeps source data at hospital premises while providing GDPR-compliant Trusted Third Party access for analysis, expert consultation, and research lifecycle management. The platform integrates health records, claims data, digital health sources, and patient-reported outcomes into a 360° view, and is reinforced by ISO 27001:2017, ISO 13485, EU MDR Class IIa, and ICH GCP certifications. Cascador delivers three main solution categories to life sciences: Market Access (market sizing, reimbursement, health economics), Clinical Evidence (outcome measurement, therapy efficacy, full study management), and Therapy Adoption (patient journey, screening, engagement). It pursues market leadership in oncology, immunology/respiratory, and neurology through its Cascador Specialties program, anchored by signature assets such as the CHRINOSOR chronic rhinosinusitis outcome registry (the largest in Europe for CRSwNP, running across 15+ clinical centres with three pharma sponsors) and the Neuroventis neurology digital platform (Helpilepsy and MigraineManager apps serving 20,000+ patients and 500+ healthcare professionals).

Cascador's business model is multi-stream. Healthcare providers receive free platform access in exchange for granting structured, anonymised data access, with Cascador earning fees on data extraction. Life sciences customers pay project-based fees for RWE studies, market access, and clinical evidence engagements, plus subscription or per-study access to the platform. The customer base includes 8 of the top 10 global pharmaceutical companies (AstraZeneca, Sanofi, UCB, ArgenX, AbbVie among named accounts). In June 2026, Cascador merged with moveUP to add eCOA/eDiary clinical trial solutions, patient support programs, and remote patient monitoring, forming the combined Cascador/moveUP entity with 35 specialists based in Brussels and Ghent, serving 100,000+ patients globally. The merger was supported by €6M in fresh capital from Qbic, Ethias Ventures, White Fund, Karista, CAREVolution, and Volta Ventures, on top of the original €3.4M seed round raised in 2022 from Qbic, Volta Ventures, Theodorus, and Hirslanden. GTM is enterprise field sales targeting top pharma, reinforced by thought leadership at ISPOR Europe, ERS, and EAACI conferences, plus educational webinars on GDPR and EU MDR compliance.

Name

Cascador Health

Legal name

Cascador Health BV

Website

https://cascador.health

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Cascador Health is a Belgian health-data platform that unlocks real-world hospital data across Europe for pharmaceutical companies, providing GDPR-compliant real-world evidence generation in oncology, immunology, and neurology. Now operating as Cascador/moveUP after a June 2026 merger with moveUP.

Ownership category

akta.pro rank

Product category

Healthcare Real-World Data Platform

NAICS

Software Publishers (5132), Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)

SIC

Services-Computer Programming, Data Processing, Etc. (7370), Services-Health Services (8000), Services-Computer Processing & Data Preparation (7374)

akta.pro primary industry

Real-World Data (RWD) Platforms & Clinical Data Curation (HLACAIAJ)

akta.pro secondary industries

De-identification, Tokenization & Privacy-Preserving Data Platforms (HLACAIAK), Data Access, Sharing & Marketplace Platforms (incl. TEFCA/QHIN enablement) (HLACAIAL), Privacy Management (Consent, DSAR, RoPA) (HDADAFAH)

Keywords

• Real-world data platform
• Clinical evidence solutions
• Healthcare data analytics
• Market access services
• Patient data integration

Headquarters

HQ city

Tielrode

HQ country

Belgium

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Data Access and Licensing Fees: Cascador charges healthcare providers a fee for data access and data extraction. Data partners receive structured data sets and full use case insights in return for granting access to their anonymized patient data. Revenue is derived from facilitating secondary use of real-world data by life sciences companies.
2. Real-World Evidence Solutions (Life Sciences): Cascador provides market access, clinical evidence, and therapy adoption solutions to pharmaceutical and medtech companies. Services include market sizing, epidemiological studies, managed entry/reimbursement, health economics assessments, outcome measurement, therapy efficacy assessment, and full 360-degree study management. Revenue is earned through project-based engagements and multi-year research programs with pharma sponsors.
3. Platform Subscription: Healthcare providers receive free use of the GDPR-compliant Cascador platform in exchange for data access. The platform is offered as a managed service with transparency and control over data. Life sciences customers access the platform on a subscription or per-study basis.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Cascador Health operates a federated software platform (Cascador Digital Suite / Cascador Edge/Merge) that unlocks structured, validated, and anonymised Real-World Data (RWD) from European healthcare providers. It acts as a Trusted Third Party providing GDPR-compliant access to data from health records, claims, and patient-reported outcomes, converting raw data into Real-World Evidence. The company sells Market Access, Clinical Evidence, and Therapy Adoption solutions to pharmaceutical and medtech clients, and builds proprietary registries such as CHRINOSOR.

Product overview

Cascador Health is a platform-based company offering the Cascador Digital Suite as its core unified product, which integrates multiple modules including Cascador Edge/Merge for data access, the Cascador RWD Access Platform for hospital data integration, and data offerings spanning raw files to consolidated reports. The company provides three main service categories: Market Access Solutions (market sizing, epidemiological studies, reimbursement support, health economics), Clinical Evidence Solutions (outcome measurement, therapy assessment, study management), and Therapy Adoption Solutions (patient journey analysis, screening, engagement, physician education). Cascador Specialties represents their therapeutic area focus, featuring the signature CHRINOSOR registry program. The portfolio was expanded through acquisitions of Galenus Health (ePROMS and analytics) and Neuroventis (neurology digital platform), with a subsequent merger with moveUP adding clinical trial solutions, patient support programs, and remote patient monitoring capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• Galenus Health: Belgian research and consultancy boutique in immunology and respiratory space, operating CHRINOSOR program for European Outcome Registry for Chronic Rhinosinusitis.
• Neuroventis
• Cascador Digital Suite
• CHRINOSOR

Products and services

• Cascador Digital Suite Gateway to secure, compliant real-world healthcare data enabling analysis of real-world data, consultation with a network of key experts, and management of research or product lifecycle from idea to adoption on one platform. Sold to life sciences companies and healthcare providers.
• Cascador Edge/Merge Digital platform providing trusted third-party access to real-world data. Collects, anonymises, and analyses data through a secure, compliant, safe and efficient system; used by healthcare providers and life sciences customers.
• Market Access Solutions Services including market sizing, epidemiological studies, managed entry and reimbursement support, and health economics assessment to help life sciences companies enter and succeed in markets.
• Clinical Evidence Solutions Services including outcome measurement, therapy efficacy assessment, therapy eligibility assessment, study support services, and full 360-degree study management for phase 4 prospective, retrospective and register-based RWD and RWE studies.
• Therapy Adoption Solutions Services including patient journey and referral assessment, patient screening, patient engagement and education, physician engagement and education, and adoption barrier assessment to bridge the evidence-practice gap.
• CHRINOSOR Program The CHronic RhINOSinusitis Outcome Registry - the largest European outcome registry for patients with chronic rhinosinusitis with nasal polyps, delivering real-world evidence on therapy efficacy, biologics therapy eligibility and prescription behaviours.
• Neuroventis Digital Platform CE-marked and FDA-registered digital care platform for neurology with Helpilepsy and MigraineManager apps supporting patients with epilepsy and headache conditions and their healthcare providers.
• Galenus Health ePROMS and Analytics Patient-reported outcome and experience measurement (ePROMS) solution integrated into the Cascador platform for real-world evidence generation, following the acquisition of Galenus Health.

Quantifiable outcome

• Six scientific publications in 2024 presented at leading congresses from the CHRINOSOR program
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered flagship, minor and core.

• moveUPflagshipStrategic or Co-development Partner · 4 June 2026Cascador Health and moveUP completed a merger in June 2026 to create a data-driven digital health powerhouse. The combined entity works with 8 of the top 10 global pharma companies and supports 100,000+ patients globally. moveUP brings clinical trial solutions (eCOA/eDiary), patient support programs, and remote patient monitoring capabilities. 35 specialists based in Brussels and Ghent. €6 million in fresh capital invested alongside the merger.
• Galenus HealthflagshipStrategic or Co-development Partner · 9 October 2024Acquired in 2024, Galenus Health is a Belgian research and consultancy boutique in immunology and respiratory space. Its CHRINOSOR program encompasses the European Outcome Registry for Chronic Rhinosinusitis with both patient-reported and physician-reported data, and brings together a network of pharma sponsors and physicians from top European clinical centres. Post-acquisition, Galenus Health co-founder Gert Mariën became Head of Sales and Joost de Kinderen became Head of Product & Insights Lab for Cascador Health.
• NeuroventisflagshipStrategic or Co-development Partner · 9 October 2024Acquired in 2024, Neuroventis is a Belgian-based CE-marked and FDA-registered digital care platform for neurology. Its apps Helpilepsy and MigraineManager support more than 20,000 epilepsy and headache patients and 500 healthcare professionals. Neuroventis co-founder Jonathan Schreiber became Chief Operating Officer of the combined entity. The platform is used by research organizations including UCB and AbbVie.
• Axon LawyersminorStrategic or Co-development Partner · 9 October 2024Joint webinar co-organised with Axon Lawyers on 'Why Real World Data is critical to comply to EU MDR regulations', covering Post-Market Surveillance and Post-Market Clinical Follow-Up requirements.
• Prof. Claus BachertcoreOthers · 9 October 2024Senior Scientific Advisor and Chair of the CHRINOSOR CRS Registry Steering Committee. Leading expert in respiratory/immunology contributing to study design, scientific publications, and engagement with top clinical centres.
• Prof. Zuzana DiamantcoreOthers · 9 October 2024Senior Scientific Advisor contributing to the academic network of key opinion leaders, research advisory board, study design, and engagement with top clinical centres in respiratory/immunology.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• IQVIA: IQVIA is the global leader in real-world evidence and clinical research, offering end-to-end RWE platforms and analytics to top-10 pharma — directly comparable to Cascador's life sciences value proposition but at vastly greater scale and breadth across geographies and therapeutic areas.
• ICON plc: ICON (including PRA Health Sciences) is a major global CRO with substantial real-world evidence capabilities serving top-10 pharma — a broader incumbent comparable to Cascador on clinical evidence and outcomes services but with global scale Cascador lacks.
• Medidata (Dassault Systèmes): Medidata offers the industry's leading eCOA/eDiary and clinical trial technology platform, complementing moveUP's clinical trial capabilities brought into the merger — directly comparable on the patient-reported outcomes and digital clinical trial infrastructure that Cascador now offers via the combined entity.

Direct peers

• Flatiron Health: Flatiron Health (acquired by Roche) operates a leading oncology-specific real-world data platform sourced from clinics and used by life sciences for evidence generation — directly comparable to Cascador's oncology specialty RWD franchise and CHRINOSOR-style specialty registries.
• Tempus Labs: Tempus operates an AI-powered real-world data and evidence platform spanning oncology and other specialties, selling to pharma for clinical decision support and trial design — a direct peer in the RWD/RWE platform category serving similar top-pharma customers.
• Aetion: Aetion is a dedicated real-world evidence analytics platform serving biopharma for regulatory-grade evidence — a direct competitor in the RWE software layer used by life sciences for market access and clinical evidence workstreams that Cascador also targets.
• ConcertAI: ConcertAI is an oncology-focused real-world data and AI platform serving top pharma for evidence generation — directly comparable to Cascador's oncology specialty data play and its CHRINOSOR model of multi-sponsor specialty evidence generation.

Regional players

• Cegedim Health Data: Cegedim Health Data operates European real-world patient databases (THIN, GERS) used by pharma for epidemiology and outcomes research — a European regional peer comparable to Cascador's pan-European hospital network data model and GDPR-compliant trusted third-party positioning.

Emerging players

• Owkin: Owkin is a federated AI-driven real-world data platform partnering with European hospitals and pharma — comparable to Cascador's federated TTP model and focus on European academic clinical centres, though Owkin leans more heavily on AI model development.
• SOPHiA Genetics: SOPHiA Genetics operates a data-driven medicine platform that aggregates genomic and clinical data from hospitals globally, including in Europe — comparable to Cascador on the federated, hospital-sourced data model and life sciences commercialization, with overlap in supporting pharma evidence generation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cascador Health